- Home
- SVRE vs CYCN Comparison
SVRE vs CYCN Comparison
Compare SVRE & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRE
- CYCN
- Stock Information
- Founded
- SVRE 2014
- CYCN 2018
- Country
- SVRE Israel
- CYCN United States
- Employees
- SVRE N/A
- CYCN N/A
- Industry
- SVRE
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- SVRE
- CYCN Health Care
- Exchange
- SVRE Nasdaq
- CYCN Nasdaq
- Market Cap
- SVRE 1.4M
- CYCN 7.6M
- IPO Year
- SVRE 2022
- CYCN N/A
- Fundamental
- Price
- SVRE $1.30
- CYCN $2.10
- Analyst Decision
- SVRE
- CYCN
- Analyst Count
- SVRE 0
- CYCN 0
- Target Price
- SVRE N/A
- CYCN N/A
- AVG Volume (30 Days)
- SVRE 98.6K
- CYCN 105.9K
- Earning Date
- SVRE 12-21-2025
- CYCN 11-13-2025
- Dividend Yield
- SVRE N/A
- CYCN N/A
- EPS Growth
- SVRE N/A
- CYCN N/A
- EPS
- SVRE N/A
- CYCN N/A
- Revenue
- SVRE $580,536.00
- CYCN $2,174,000.00
- Revenue This Year
- SVRE $458.76
- CYCN N/A
- Revenue Next Year
- SVRE $106.57
- CYCN N/A
- P/E Ratio
- SVRE N/A
- CYCN N/A
- Revenue Growth
- SVRE 13.19
- CYCN N/A
- 52 Week Low
- SVRE $1.20
- CYCN $1.27
- 52 Week High
- SVRE $106.53
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- SVRE 35.75
- CYCN 36.62
- Support Level
- SVRE $1.20
- CYCN $2.23
- Resistance Level
- SVRE $1.36
- CYCN $2.46
- Average True Range (ATR)
- SVRE 0.09
- CYCN 0.15
- MACD
- SVRE 0.00
- CYCN -0.03
- Stochastic Oscillator
- SVRE 25.64
- CYCN 9.40
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road and pedestrians. Geographially, it operates in Israel and Europe, out of which it derives maximum revenue from Israel.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.